Skip to content

Study · Non-randomized trial · 2020

9 results

The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.

Urva S, Coskun T, Loghin C, Cui X, Beebe E, O'Farrell L, Briere DA, Benson C, Nauck MA, Haupt A

Diabetes, obesity & metabolism13 Jul 2020Cited by 112 (Europe PMC)

PMID32519795 (opens in a new tab)PMCIDPMC7539915 (opens in a new tab)DOI10.1111/dom.14110 (opens in a new tab)PepBankPUB-32519795
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In participants with diabetes, tirzepatide delayed gastric emptying after a single dose.

    In plain wordsIn people with diabetes, one tirzepatide dose slowed stomach emptying.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSingle-dose gastric emptying in diabetes
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    ≥5 mg once weeklyAs given in this study (human).

    Source sentences

    Summary
    In participants with and without T2DM, once-weekly tirzepatide (≥5 and ≥4.5 mg, respectively) delayed GE after a single dose.
    1 context sentence
    Summary · context
    Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In participants without diabetes, tirzepatide delayed gastric emptying after a single dose.

    In plain wordsIn people without diabetes, one tirzepatide dose slowed stomach emptying.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSingle-dose gastric emptying without diabetes
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    ≥4.5 mg once weeklyAs given in this study (human).

    Source sentences

    Summary
    In participants with and without T2DM, once-weekly tirzepatide (≥5 and ≥4.5 mg, respectively) delayed GE after a single dose.
    1 context sentence
    Summary · context
    Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy participants, the gastric emptying delay diminished after multiple tirzepatide doses.

    In plain wordsIn healthy people, stomach emptying slowed less after repeated tirzepatide doses.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAttenuation of gastric emptying delay
    Study

    n: not reported in source

    Comparator
    Initial single-dose response
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    This effect diminished after multiple doses of tirzepatide or dulaglutide in healthy participants.
    1 context sentence
    Summary · context
    Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy participants, the gastric emptying delay diminished after multiple dulaglutide doses.

    In plain wordsIn healthy people, stomach emptying slowed less after repeated dulaglutide doses.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAttenuation of gastric emptying delay
    Study

    n: not reported in source

    Comparator
    Initial single-dose response
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    This effect diminished after multiple doses of tirzepatide or dulaglutide in healthy participants.
    1 context sentence
    Summary · context
    Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo.
  5. 05HumanNon-randomized trialEfficacy outcome

    In participants with diabetes, residual gastric emptying delay remained after multiple escalating tirzepatide doses.

    In plain wordsIn people with diabetes, stomach emptying remained slower after repeated escalating tirzepatide doses.

    Peptide
    Tirzepatide
    Outcome
    DecreaseResidual gastric emptying delay
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    5/5/10/10 or 5/5/10/15 mg · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    In participants with T2DM treated with an escalation schedule of tirzepatide 5/5/10/10 or 5/5/10/15 mg, a residual GE delay was still observed after multiple doses.
    1 context sentence
    Summary · context
    Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In obese mice, tirzepatide delayed gastric emptying similarly to semaglutide.

    In plain wordsIn mice, tirzepatide delayed stomach emptying similarly to semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAcute gastric emptying
    Study

    mousen: not reported in source

    diet-induced obese mice
    Comparator
    Semaglutide
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In mice, tirzepatide delayed GE to a similar degree to that achieved with semaglutide;
    1 context sentence
    Summary · context
    GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In obese mice, semaglutide delayed gastric emptying similarly to tirzepatide.

    In plain wordsIn mice, semaglutide delayed stomach emptying similarly to tirzepatide.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute gastric emptying
    Study

    mousen: not reported in source

    diet-induced obese mice
    Comparator
    Tirzepatide
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In mice, tirzepatide delayed GE to a similar degree to that achieved with semaglutide;
    1 context sentence
    Summary · context
    GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In obese mice, the acute gastric emptying inhibition disappeared after repeated tirzepatide treatment.

    In plain wordsIn mice, tirzepatide's initial slowing of stomach emptying disappeared after repeated treatment.

    Peptide
    Tirzepatide
    Outcome
    No significant changeLoss of gastric emptying inhibition
    Study

    mousen: not reported in source

    diet-induced obese mice
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In mice, tirzepatide delayed GE to a similar degree to that achieved with semaglutide; however, these acute inhibitory effects were abolished after 2 weeks of treatment.
    1 context sentence
    Summary · context
    GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In obese mice, the acute gastric emptying inhibition disappeared after repeated semaglutide treatment.

    In plain wordsIn mice, semaglutide's initial slowing of stomach emptying disappeared after repeated treatment.

    Peptide
    Semaglutide
    Outcome
    No significant changeLoss of gastric emptying inhibition
    Study

    mousen: not reported in source

    diet-induced obese mice
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In mice, tirzepatide delayed GE to a similar degree to that achieved with semaglutide; however, these acute inhibitory effects were abolished after 2 weeks of treatment.
    1 context sentence
    Summary · context
    GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Versions 2 to 3

    21 Oct 2026, 18:59 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:07 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.